KOSDAQBiotech & Pharma220100

FutureChem

₩5,750▼ 1.03%2026-11-18 close
Market Cap
₩178.1B
Turnover
₩200M
Volume
30K
Shares out.
31M
PER
—
PBR
2.6×
EPS
-₩446
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Prostavue sales begin as losses persist ahead of FC705 data

FutureChem has entered a commercialization phase, with Prostavue's first sales and FC705 trial data in focus, but operating losses have continued for five consecutive quarters, making the pace of profitability recovery the next point to track.

  1. 1

    On a disclosed basis, 2025 revenue rose 8.0% year on year to KRW 18.7 billion, and the operating loss narrowed to KRW 7.75 billion from KRW 9.47 billion in 2024.

  2. 2

    Third-quarter 2026 revenue reached KRW 4.7 billion, up 24.0% from a year earlier, but the company still posted an operating loss of KRW 1.87 billion and a net loss attributable to controlling shareholders of KRW 3.21 billion.

  3. 3

    The prostate cancer diagnostic Prostavue (FC303) received marketing approval on May 4, 2026, and the company announced its first sales on August 20, 2026.

  4. 4

    Topline results from the U.S. Phase 2a trial of the therapy FC705 were announced on October 23, 2026, and the company said it is negotiating technology transfer deals with global pharmaceutical companies.

  5. 5

    The rights offering of about KRW 40 billion and the bonus issue decided in May 2026 bring both funding for clinical work and a larger share count.

02

Business structure

FutureChem began in 2001 by manufacturing and selling radiopharmaceutical precursors, then expanded into developing and producing radiopharmaceutical drugs, producing precursors and synthesis reagents, and selling automated synthesis devices. It listed on KOSDAQ in 2016.

Its main products are the Alzheimer's diagnostic Alzavue and the Parkinson's diagnostic PDVUE, and Prostavue, the prostate cancer diagnostic that received approval in May 2026, was added as its fourth diagnostic radiopharmaceutical.

Prostavue is a PET diagnostic that binds fluorine-18 to a peptide targeting PSMA, a prostate-specific protein. According to the business report, 2025 standalone revenue was about KRW 8.55 billion, and diagnostic radiopharmaceutical products and merchandise made up more than about 70% of it.

Precursors, reagents and automated synthesis devices account for the rest. The treatment pipeline includes FC705, a prostate cancer-targeted radiotherapy, which is in Phase 3 in Korea and has reported Phase 2a results in the United States. Subsidiaries include FutureChem Healthcare, SI Healthcare and FutureChem U.S.A.

Customers are mainly hospitals and medical institutions. The company highlights Phase 3 results showing that Prostavue's positive predictive value is higher than that of conventional imaging (CT, MRI and bone scan). However, direct comparisons with other PSMA diagnostics have not been fully presented in company materials.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.8B-₩2.5B−66.7%
2025Q4₩6.2B-₩1.4B−22.9%
2026Q1₩6.4B-₩2.2B−34.8%
2026Q2₩4.3B-₩3.2B−75.4%
2026Q3₩4.7B-₩1.9B−39.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩12.6B-₩12.9B-₩14B−102.9%−19.9%26.2%
2023₩14B-₩8.4B-₩6.7B−60.2%−10.5%14.0%
2024₩17.3B-₩9.5B-₩9.4B−54.7%−17.3%36.5%
2025₩18.7B-₩7.8B-₩11.3B−41.5%−20.6%35.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

On a disclosed basis, annual revenue went from KRW 12.6 billion in 2022 to KRW 14 billion in 2023 (up 11.1% year on year), KRW 17.3 billion in 2024 (up 23.8%) and KRW 18.7 billion in 2025 (up 8.0%).

Revenue has risen for three consecutive years from 2023 through 2025, and 2025 was the largest year of the 2022–2025 period. Operating losses were KRW 12.9 billion in 2022, KRW 8.41 billion in 2023, KRW 9.47 billion in 2024 and KRW 7.75 billion in 2025, a loss in each of the four years.

The operating margin improved from -102.9% in 2022 to -60.2% in 2023, -54.7% in 2024 and -41.5% in 2025. The net loss attributable to controlling shareholders narrowed to KRW 6.71 billion in 2023, then widened to KRW 9.42 billion in 2024 and KRW 11.3 billion in 2025.

The net loss including non-controlling interests was KRW 9.43 billion in 2024. At the end of 2025, total equity was KRW 54.8 billion, of which KRW 54.7 billion belonged to controlling shareholders, and total liabilities were KRW 19.7 billion. The debt ratio was 14.0% in 2023, rising to 36.5% in 2024 and 35.9% in 2025.

Operating cash outflow narrowed from KRW 7.61 billion in 2022 to KRW 2.43 billion in 2025.

On a quarterly basis, revenue was KRW 3.79 billion in the third quarter of 2025, KRW 6.16 billion in the fourth quarter (up 62.5% from the prior quarter), KRW 6.36 billion in the first quarter of 2026, KRW 4.27 billion in the second quarter (down 32.9% from the prior quarter) and KRW 4.7 billion in the third quarter of 2026.

The operating loss narrowed from KRW 2.53 billion in the third quarter of 2025 to KRW 1.41 billion in the fourth quarter, widened to KRW 3.22 billion in the second quarter of 2026, and was KRW 1.87 billion in the third quarter of 2026.

The company posted a net profit attributable to controlling shareholders of KRW 2.31 billion in the second quarter of 2026, turning to a net loss of KRW 3.21 billion in the third quarter.

In its preliminary first-quarter 2026 announcement on May 15, 2026, the company said gross profit rose 85% year on year to about KRW 1.6 billion.

An August 18, 2026 company announcement put first-half 2026 revenue at KRW 10.63 billion, up 22.0%, and the operating loss at KRW 5.43 billion, matching the sum of the disclosed quarters. The company attributed the wider first-half operating loss to higher R&D spending.

05

Industry analysis

Radiopharmaceuticals bind radioactive isotopes to target molecules for diagnosis or treatment.

Diagnostic agents are used to locate lesions on PET imaging, and Prostavue is fluorine-18 based with a half-life of about 110 minutes, which the company cites as a commercial advantage for mass production and multi-site supply.

Prostate cancer is the most common cancer among men in the United States, with about 330,000 new patients a year reported for 2026.

On the treatment side, PSMA-targeted radioligand therapies draw interest from global pharmaceutical companies, and the company says FC705 is being developed to achieve tumor uptake at a lower dose than existing therapies. The company said its U.S.

Phase 2a was designed in a way similar to commercialized prostate radiotherapies so that tumor uptake and safety data can be compared on the same basis. In competition, FutureChem points to its existing diagnostic lineup for Alzheimer's and Parkinson's and its automated synthesis devices as differentiators.

Verified data on competitors' sales and market share are limited to company materials. On the overseas side, a June 2026 news report said FutureChem recovered European rights to FC303 from a partner early and is in talks with two new partners.

06

Outlook

In Korea, the first sales of Prostavue were announced on August 20, 2026, and the company plans to expand the number of supplying medical institutions in stages.

Overseas, the company said on August 18, 2026 that the China Phase 3 of FC303 has been completed and that it plans to apply for marketing approval with China's drug regulator; no approval timing has been disclosed. In a shareholder letter, the company said it expects 2026 consolidated revenue to grow by 30% or more.

First-half 2026 revenue grew 22.0%, so meeting that target would require faster growth in the second half than in the first. On the treatment side, topline results from the U.S. Phase 2a trial of FC705 were announced on October 23, 2026.

The CEO said complete responses were seen in 5 of 18 evaluable patients, and the PSA50 response rate was reported at 58.8%. Based on these results, the company is negotiating technology transfer with global pharmaceutical companies and says it aims for FC705 to be best in class.

The proceeds of the roughly KRW 40 billion rights offering are planned for FC705 clinical costs and new pipelines, including pancreatic cancer and triple-negative breast cancer. In June 2026, the company also joined a Korean ARPA-H consortium project with Seoul National University Hospital and others.

07

Valuation

PER
—
PBR
2.6×
ROE
-17.2%
EPS
-₩446
BPS
₩2,531
Dividend per share
₩0

Because the net loss attributable to controlling shareholders over the last four quarters is negative, the price-to-earnings ratio cannot be calculated, so the stock cannot be compared with earnings-based multiples.

Valuation discussion therefore rests more on business milestones such as clinical data and technology transfer. The price-to-book ratio sits in a range carrying a premium over book value, meaning the share price reflects pipeline value on top of the asset base.

The company does not pay dividends, so cash returns to shareholders are not part of the current picture. Total equity of KRW 54.8 billion at the end of 2025 is the reference point for the asset base, and the 2026 rights and bonus issues increased the share count, which matters when reading per-share measures.

The shift from loss to profit appeared in only one quarter of 2026, and the annual result is still a loss. The starting point for valuation discussion is therefore the pace of operating loss reduction and the growth of Prostavue sales rather than multiple comparisons.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

Diagnostic product enters commercialization

Prostavue received marketing approval on May 5, 2026, and first sales were announced on August 20, 2026. The company describes it as its fourth diagnostic radiopharmaceutical. Third-quarter 2026 revenue of KRW 4.7 billion rose 24.0% year on year. The company plans to expand supplying hospitals in stages.

Cost structure and narrowing losses

The operating margin improved from -102.9% in 2022 to -41.5% in 2025. The operating loss narrowed to KRW 7.75 billion in 2025 from 2024. In its preliminary first-quarter 2026 release, the company said gross profit rose 85% year on year.

The third-quarter 2026 operating loss of KRW 1.87 billion was smaller than the KRW 3.22 billion in the second quarter.

FC705 data and technology transfer talks

Topline results from the U.S. Phase 2a trial of FC705 were announced on October 23, 2026. The CEO said complete responses occurred in 5 of 18 evaluable patients, and the PSA50 response rate was 58.8%. The company said it is negotiating technology transfer with global pharmaceutical companies based on these results. It described its aim for FC705 as best in class.

09

Bear factors

Continued losses and wider losses in some periods

The operating loss was recorded in each of the four years from 2022 to 2025. The net loss attributable to controlling shareholders widened to KRW 11.3 billion in 2025 from KRW 9.42 billion in 2024. The four-quarter total of such losses through the third quarter of 2026 is KRW 10.5 billion. The third quarter of 2026 still showed an operating loss of KRW 1.87 billion.

Uneven growth pace

Second-quarter 2026 revenue of KRW 4.27 billion fell 32.9% from the prior quarter. First-half revenue growth of 22.0% is below the 30% or more the company expects for the full year. Quarterly revenue has been uneven, so achieving the annual target depends on the second half.

After the second-quarter profit, a loss reappeared in the third quarter, so whether quarterly profit recurs is the next point to check.

Funding needs and a larger share count

The company decided on a rights offering of about KRW 40 billion, with new shares of 3,389,830 at a planned issue price of KRW 11,800 per share. A bonus issue of 0.2 shares per common share would issue 5,163,450 shares. A larger share count dilutes per-share measures, and continued clinical spending keeps funding needs high.

10

Risk factors

Regulatory and approval

In March 2026, the Ministry of Food and Drug Safety issued a warning over procedural violations found while checking the reliability of data for the FC303 approval application. The company said the data were not compromised and that corrective and preventive actions were completed.

The timing and outcome of the China approval application have not been disclosed. Any delay in regulatory timelines could affect the revenue plan.

Clinical uncertainty

The U.S. Phase 2a trial of FC705 evaluated only 18 patients, a small sample. Complete responses in 5 patients come from a small early-stage study and should be read alongside later data. Results of the Korean Phase 3 study and the final approval timing have not been fixed. Technology transfer terms may change depending on how the clinical data are interpreted.

Funding and dilution

The company announced a roughly KRW 40 billion rights offering and a bonus issue to be carried out in the second half of 2026. The proceeds were disclosed as operating funds, and actual spending should be checked in later reports.

The debt ratio was 35.9% at the end of 2025, but while operating losses continue, further funding needs remain. A larger share count lowers existing shareholders' stake.

11

What to watch next

  1. End of March 2027 (annual report deadline)

    Check whether 2026 annual revenue growth reaches the 30% or more the company has projected, along with the operating loss trend, FC705 clinical spending and how the rights offering proceeds were used.

  2. By May 15, 2027 (first-quarter report deadline)

    Track how much quarterly Prostavue revenue has grown and whether the operating loss continues for a sixth consecutive quarter. Also check whether revenue declines from the prior quarter, like the one in the second quarter of 2026, recur.

  3. First half of 2027 (timing not yet set)

    Watch the outcome and timing of the China marketing approval application for FC303. Whether overseas sales begin to contribute is a key basis for broader commercialization.

  4. After late 2026 (company timing not yet set)

    Check the detailed U.S. Phase 2a data release and whether a technology transfer agreement is signed with a global pharmaceutical company. Contract terms and upfront payments will be the benchmark for pipeline value.

12

Overall view

FutureChem has entered a stage of broadening its product revenue base with the approval and first sales of the diagnostic Prostavue. On a disclosed basis, annual revenue has risen for three consecutive years from 2023 through 2025, and the operating margin improved from -102.9% in 2022 to -41.5% in 2025.

However, operating losses have been recorded for four consecutive years and for five consecutive quarters through the third quarter of 2026. The return to profit in the second quarter of 2026 lasted only one quarter. The U.S.

Phase 2a results for the therapy FC705 and the technology transfer talks are key variables for pipeline value, but the trial sample is small and the data are at an interim stage.

The company's expectation of 30% or more annual revenue growth in 2026 compares with 22.0% growth in the first half, so the second half would need to accelerate. The roughly KRW 40 billion rights offering provides funding but also increases the share count.

The next checkpoints are the annual revenue growth and operating loss trend in the 2026 annual report, and whether a FC705 technology transfer agreement is signed.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. futurechem.co.kr
  2. view.asiae.co.kr
  3. openbizdata.com
  4. v.daum.net
  5. comp.wisereport.co.kr
  6. pinpointnews.co.kr
  7. markets.hankyung.com
  8. saramin.co.kr
  9. newspim.com
  10. m.news.nate.com
  11. hankyung.com
  12. newspim.com
  13. news.nate.com
  14. datatooza.com
  15. newstown.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis